|Datasheet||Specific References||Reviews||Related Products||Protocols|
|ORF Clone of Homo sapiens CD82 molecule DNA.|
|R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27, CD82|
|Identical with the Gene Bank Ref. ID sequence.|
|Whatman FTA elute card (Cat: WB120410) contains 5-10 μg of plasmid.|
|The Whatman FTA elute card can be stored at room temperature for three months under dry condition.|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Human CD82 Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||HG12275-G-F|
|Human CD82 Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||HG12275-G-H|
|Human CD82 Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||HG12275-G-M|
|Human CD82 Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||HG12275-G-N|
|Human CD82 Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||HG12275-G-Y|
|Product name||Product name|
CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.